Chiltern Finalizes Acquisition of Theorem Clinical Research
(London, U.K., and Wilmington, N.C.; Sept. 14, 2015) - Chiltern, a leading global contract research organization (CRO), has completed its acquisition of Theorem Clinical Research, strengthening its position as the largest mid-sized provider of comprehensive, yet flexible and responsive, clinical development services.
Chiltern now comprises 3,700 people across 47 countries, expanding Chiltern’s footprint in Europe, North America and Asia-Pacific. The acquisition enhances Chiltern’s Oncology, Biopharma and Source offerings, broadens its therapeutic expertise and establishes new capabilities in medical device and diagnostics, clinical analytics and clinical supplies.
“By bringing Chiltern and Theorem together, we have created a unique, mid-sized research partner focused on providing exceptional scientific expertise and personal service,” said Dr. Jim Esinhart, Chiltern CEO. “Clients can expect the same high level of service, now with expanded capabilities. Senior leadership will still be involved in running trials.”
“The acquisition of Theorem marks an important milestone for Chiltern,” said Nick Thornton, Chiltern chairman. “We stayed true to our mission to be a responsive, client-centric mid-sized provider, yet we enhanced our geographic coverage and service offerings in key areas. We are delighted to welcome the dynamic Theorem team to Chiltern and are pleased to announce that Dr. John Potthoff, Theorem’s president and CEO, has joined our board as a non-executive director.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
